ArticleMolecular biology reports2026
PYCR1 modulates ferroptosis and malignant phenotypes of clear cell renal cell carcinoma through proline biosynthesis.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundPyrroline-5-carboxylate reductase 1 (PYCR1), a key enzyme in proline biosynthesis, has been implicated in various cancers. However, its role in clear cell renal cell carcinoma (ccRCC) remains elusive.
methodsWe analyzed PYCR1 expression and its correlation with clinicopathological features using the UALCAN platform based on TCGA data. Functional roles of PYCR1 in cell proliferation and migration were assessed using CCK-8, colony formation, and wound healing assays in ccRCC cell lines (769P and 786O). The regulatory mechanism of PYCR1 in ferroptosis was investigated through pharmacological induction and molecular biology techniques.
resultsPan-cancer analysis revealed significant upregulation of PYCR1 in 22 malignancies, with particularly robust overexpression in ccRCC tissues and cell lines compared to normal controls. High PYCR1 expression was positively correlated with advanced pathological stages, nodal metastasis, and poor prognosis in ccRCC patients. Functionally, PYCR1 overexpression promoted, while its knockdown suppressed, proliferation and migration of ccRCC cells. Mechanistically, PYCR1 was found to inhibit ferroptosis by regulating intracellular iron homeostasis and the antioxidant system: PYCR1 depletion increased intracellular Fe²⁺ accumulation and lipid peroxidation, decreased glutathione (GSH) content, and downregulated key ferroptosis regulators (GPX4, FSP1, SLC7A11). Importantly, these effects were reversed by proline supplementation, indicating that PYCR1-mediated proline reprogramming is essential for suppressing ferroptosis.
conclusionOur findings indicate that PYCR1 functions as an oncogene in ccRCC to facilitate tumor progression and suppress ferroptosis predominantly via proline synthesis, while other unelucidated parallel regulatory pathways may also participate in this biological process. Hence, PYCR1 is expected to serve as a promising prognostic biomarker and therapeutic candidate for ccRCC.
Indexed as
Identifiers
42334666What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.